Kite Pharma, a unit of Gilead (GILD), was granted FDA orphan designation for its treatment of multiple myeloma, according to a post to the agency’s website.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Private Markets: Microsoft, Nvidia to invest in Anthropic
- Gilead price target raised to $140 from $131 at Mizuho
- Gilead Sciences Announces Executive Vice President Departure
- 3 Stocks Flashing ‘Buy Now’ Signals on Technical Charts
- Gilead announces delivery of first lenacapavir shipments to Eswatini, Zambia